Atomoxetine as a Viable ADHD Treatment in Breastfeeding Mothers: Evidence From Human Milk Pharmacokinetic Analysis

Atomoxetine is a selective norepinephrine reuptake inhibitor prescribed for the management of attention-deficit hyperactivity disorder (ADHD).  In this podcast, Emily Yamada discusses her article "Atomoxetine as a Viable ADHD Treatment in Breastfeeding Mothers: Evidence From Human Milk Pharmacokinetic Analysis." In their article, Yamada and her colleagues present data showing that there is minimal transfer of atomoxetine in breast milk, suggesting that maternal atomoxetine use poses a very low risk to breastfed infants, making it a suitable choice for medication management of ADHD in lactating women. The other contributing authors are Shraddha Trehan, Amy Stark, Kaytlin Krutsch, and Palika Datta. The article is published in the January-February 2026 issue of The Journal of Clinical Psychopharmacology. doi: 10.1097/JCP.0000000000002109